SARS-CoV-2 Infection Leads to Neurological Dysfunction
Journal of Neuroimmune Pharmacology, ISSN: 1557-1904, Vol: 15, Issue: 2, Page: 167-173
2020
- 69Citations
- 280Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations69
- Citation Indexes68
- 68
- CrossRef27
- Policy Citations1
- 1
- Captures280
- Readers280
- 280
- Mentions1
- News Mentions1
- 1
Most Recent News
08.07.20 | Neurologic Complications of COVID-19
| Neurologic Complications of COVID-19 12 views Share Like ... Published on Aug 12, 2020 Scott Letendre, MD Professor in Residence Division of Infectious Diseases
Article Description
A number of neurological disease complications have been seen following infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While most person with COVID-19 respiratory disease demonstrate headache, nausea and vomiting, up to 40% present also experience dizziness, confusion, cerebrovascular disease, muscle pain, ataxia and seizures. Loss of taste and smell, defects in visual acuity and pain occur in parallel. Such central nervous system (CNS) signs and symptoms linked to laboratory-confirmed SARS-CoV-2 infection is often life threatening. Health care providers currently evaluating patients with neurologic symptoms need consider COVID-19 in any differential diagnosis. These considerations will facilitate prompt testing, isolation and prevention of viral transmission speeding best clinical outcomes. [Figure not available: see fulltext.].
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85085285043&origin=inward; http://dx.doi.org/10.1007/s11481-020-09924-9; http://www.ncbi.nlm.nih.gov/pubmed/32447746; https://link.springer.com/10.1007/s11481-020-09924-9; https://dx.doi.org/10.1007/s11481-020-09924-9; https://link.springer.com/article/10.1007/s11481-020-09924-9
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know